Galtes

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galtes

Quick Facts

Property Description
Active ingredient Gliclazide
Form Oral tablet (often modified-release)
Pharmacological class Sulfonylurea, Anti-diabetic agent
General purpose To lower elevated blood glucose levels
Origin Synthetic compound

Galtes: Defining the Oral Anti-diabetic Agent

Galtes is a prescription-only medication defined as an oral anti-diabetic agent, administered via the oral route. Its single active ingredient is Gliclazide, which firmly establishes the drug within the sulfonylurea pharmacological class. Gliclazide is recognized as a potent, second-generation derivative of this group, used for the management of high blood sugar. Gliclazide is a clinically recognized oral hypoglycemic agent.

This classification identifies Galtes as a synthetic compound and a crucial part of pharmacotherapy. A key distinguishing feature of Gliclazide, especially in its modern applications, is its frequent formulation as a modified-release oral tablet. This specific form is designed to ensure a more controlled and sustained release of the active compound following ingestion, supporting continuous glycemic control for adult patients.

Gliclazide: Composition and General Therapeutic Purpose

The core component of Galtes is Gliclazide, an insulin secretagogue compound, which constitutes the sole therapeutic element. The tablet composition includes this active ingredient alongside necessary solid pharmaceutical excipients—such as binders and fillers—which are essential for the physical integrity and release profile of the dosage form. The compound is widely recognized for its clinical utility in diabetes management.

As an insulin secretagogue, the general therapeutic purpose of Galtes is to actively assist the body in regulating its blood sugar. The drug achieves this by promoting the release of insulin that is stored within the pancreatic beta-cells. This targeted action is fundamental to the medicine’s role in a typical use scenario: helping to lower elevated blood glucose levels in adult patients who still possess some insulin-producing capacity, thereby assisting in the maintenance of stable glycemic control.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Galtes?

Possible Side Effects and Safety Information

The safety profile of Galtes (Gliclazide) is formally documented in regulatory sources by classifying potential adverse reactions according to frequency and the body system affected. The primary safety concern associated with this medicine is Hypoglycaemia (low blood sugar), which is officially classified as a Common adverse reaction, meaning it may affect up to 1 in 10 people.

Documented Adverse Reactions

Classification System-Organ-Class Examples of Reactions
Common Metabolism and nutrition disorders Hypoglycaemia (low blood sugar)
Uncommon Gastrointestinal disorders Nausea, vomiting, dyspepsia, abdominal pain
Rare Blood and lymphatic system disorders Changes in blood counts (e.g., leucopenia, agranulocytosis)
Rare Hepatobiliary disorders Hepatitis, jaundice, elevated liver enzymes

Adverse reactions affecting the skin and subcutaneous tissue are also documented, including rash, itching, and urticaria.

High-Level Safety Considerations

The risk of developing Hypoglycaemia is explicitly noted in official labeling to be increased at the beginning of treatment or during periods of dose adjustment.

Regulatory documents also list several Serious Adverse Reactions, which, though rare, are clinically significant. These include severe cases of Hypoglycaemia and potentially life-threatening dermatological reactions such as bullous reactions, as well as cases of acute hepatic failure.

Safety is formally restricted in certain populations. Galtes is contraindicated in patients with severe renal or hepatic insufficiency due to the significantly heightened and prolonged risk of severe Hypoglycaemia. The medicine is also restricted for use in those with Insulin-Dependent Diabetes Mellitus (Type 1 Diabetes) and individuals with known hypersensitivity to other sulfonylurea or sulfonamide derivatives.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Galtes (Gliclazide) is officially documented to result in severe and prolonged hypoglycemia, which constitutes a medical emergency. The clinical manifestations arise from dangerously low blood sugar affecting the central nervous system (CNS) and cardiovascular system.

Documented Manifestations and Severe Outcomes

The initial presentation often includes signs such as sweating, tremor, headache, nervousness, and confusion. Regulatory documentation highlights that this can progress to severe neuroglycopenic outcomes, including convulsions, profound coma, and temporary or permanent impairment of brain function. Life-threatening cardiovascular effects, such as cardiac arrhythmia and angina pectoris, are also listed as potential complications during a severe episode.

Mandatory Emergency Action

Government health authorities explicitly state that immediate medical treatment or even hospitalization is required for any episode classified as severe or prolonged hypoglycemia. This urgent action is necessary to facilitate the prompt administration of glucose, which is the specific intervention mandated to counteract the overdose effect. Close medical monitoring must be continued for 24 hours or more due to the documented risk of hypoglycemia recurrence. Furthermore, patients who are elderly or have impaired hepatic or renal function are recognized as having an increased susceptibility to severe or prolonged overdose manifestations.

Therapeutic Uses of Galtes

Main Uses and Benefits of Galtes (Gliclazide)

Galtes is commonly used for managing the symptoms of Type 2 Diabetes Mellitus. It is applied when lifestyle measures alone are insufficient, or may be part of symptomatic management as an addition to existing therapy, to support patients during difficult episodes and assist with glycemic control. The medication is used in adults when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose.

This medication is relevant for easing symptoms linked to symptoms related to systemic imbalance, specifically the persistent, pathological elevation of blood sugar, including high Fasting Plasma Glucose and high long-term average blood sugar, measured as Glycosylated Hemoglobin (HbA1c). Galtes helps address symptom clusters of Postprandial Glucose Spikes, which are the sudden, excessive rises in blood sugar that typically follow meals. This benefit may assist with maintaining functional stability, which contributes to improved comfort during symptomatic periods by managing glucose fluctuation.

A recognized therapeutic benefit of Galtes is relevant in contexts involving heightened systemic burden related to vascular function. This benefit may be part of symptomatic management and supports general well-being during symptomatic phases.

Quick Fact: Relief for HbA1c
Primary Goal Assisting with maintaining a sense of stability in chronic blood sugar levels.
Symptom Category Symptoms related to systemic imbalance and chronic blood glucose elevation.
Context of Use Often used during phases when symptoms become more noticeable due to inadequate control with diet/exercise.

Eligibility and Restrictions for Use

Who Can and Cannot Use Galtes?

Galtes (Gliclazide) is a prescription-only medication whose use is strictly governed by regulatory documentation regarding patient eligibility and non-eligibility.


Eligibility Status Population Restriction (Official Labeling)
Allowed Use Adults with Type 2 Diabetes Mellitus when control is insufficient with diet and exercise.
Conditional Use Older Adults and patients with mild to moderate renal/hepatic impairment require careful clinical monitoring.
Not Recommended Pediatric patients (children and adolescents) as safety and effectiveness have not been established.

Absolute Contraindications

Use of Galtes is strictly prohibited in the following populations and conditions, as stated by regulatory agencies:

  • Type 1 Diabetes Mellitus (Insulin-dependent diabetes).
  • Severe Renal or Severe Hepatic Insufficiency (kidney or liver failure).
  • Diabetic Ketoacidosis, Diabetic Coma, or Pre-Coma.
  • Pregnancy and Lactation (Breastfeeding).
  • Known Hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.
  • Concurrent treatment with miconazole (systemic or oromucosal gel).

Additionally, Galtes must be temporarily discontinued and substituted with insulin during periods of acute stress, trauma, or surgery.

What should I know about interactions with other medicines?

The interaction profile of Galtes (Gliclazide) is defined by documented substance combinations that formally alter its blood glucose-lowering action, based strictly on official regulatory labeling.

Official Interaction Restrictions and Classifications

Classification Restriction / Context
Contraindicated Combination Miconazole (systemic route or oromucosal gel) is formally prohibited due to the risk of severe potentiation of the hypoglycaemic effect, leading to coma.
Pharmacokinetic Alteration Co-administration with Phenylbutazone (systemic route) increases Gliclazide exposure by reducing its elimination and/or displacing it from plasma proteins.
Decreased Exposure Risk The herbal product St John's Wort (Hypericum perforatum) is documented to decrease Gliclazide exposure due to increased apparent clearance, which may result in reduced efficacy.

Documented Pharmacodynamic and Substance Interactions

  • Potentiating Agents: The blood glucose lowering effect is potentiated when Galtes is co-administered with other anti-diabetic agents, Beta-blockers, Fluconazole, ACE inhibitors, NSAIDs, and MAOIs, among others. This potentiation increases the risk of hypoglycemia.
  • Counteracting Agents: Agents such as Glucocorticoids and Danazol may counteract the effect of Galtes, leading to an increase in blood glucose levels.
  • Alcohol: Alcohol causes a pharmacodynamic interaction that increases the hypoglycaemic reaction by inhibiting the body's compensatory metabolic responses; its co-administration should be avoided.

Population-Specific Notes

The regulatory profile specifies that interaction effects may be prolonged in cases of severe hepatic or renal insufficiency. Additionally, disturbances in blood glucose (dysglycemia) have been specifically reported in elderly patients receiving concomitant Fluoroquinolones.

Mechanism of Action

How Galtes Works

Galtes is an agent that operates by engaging specific mechanisms to modulate overactive or dysregulated processes at a molecular level. It influences equilibrium within targeted biological pathways, resulting in the modification of heightened physiological responses through its mechanism of action.


Modulation of Receptor-Mediated Signaling

Galtes acts within domains involving receptor-mediated signaling by initiating or suppressing the early molecular steps that shape systemic physiological outcomes. This mechanism alters pathway activity associated with signal escalation, leading to reduction of excessive mediator activity within affected systems.


Influence on Pathway Feedback Regulation

The drug engages mechanisms that influence feedback regulation within pathways, affecting systems where distinct signaling patterns dominate. By modifying these cascades, Galtes regulates processes driven by these patterns, which leads to resulting physiological adjustments and shapes the drug’s overall effect profile.


Attenuation of Overactive Processes

A key effect of Galtes involves its ability to modify early molecular steps that drive systemic effects, particularly in cascades where multiple layers of pathway activation occur. This action modifies overactive physiological responses and influences equilibrium within targeted biological systems.

Dosage and Administration Information

How to Use Galtes

Administration of Galtes (Gliclazide) is strictly via the oral route, typically using the modified-release (MR) tablet formulation. The use of this medication is governed by specific instructions established in product monographs and clinical labeling.


Official Dosing and Frequency

The standard adult regimen for the modified-release tablet specifies a starting dose of 30 mg once daily. The maximum daily dose is 120 mg. The maximum dose should not be exceeded. Dose adjustments are carried out methodically: increases, usually in 30 mg steps, are typically separated by an assessment period of at least one month to determine the clinical response.

Parameter Modified-Release (MR) Tablet Regimen
Route Oral
Frequency Once daily
Starting Dose 30 mg
Maximum Daily Dose 120 mg

Contextual Use Instructions

The once-daily dose of the MR tablet must be taken as a single intake at breakfast time (or the first meal of the day). The tablets must be swallowed whole with water and must not be crushed or chewed to ensure the integrity of the modified-release mechanism.

If a dose is forgotten, the standard instructions state that the user must not increase the dose taken the next day. The missed dose should be skipped, and the subsequent dose should be taken at the usual time. Regarding population-specific instructions, the standard adult regimen generally applies to older adults (aged 65 and over), but the use of Galtes is not recommended for children and adolescents due to insufficient data on safety and efficacy.

Recent Clinical Evidence

Recent clinical evidence for Galtes, a therapeutic agent targeting the Galectin-3 protein, has primarily focused on its potential role in managing Non-Alcoholic Steatohepatitis (NASH) with cirrhosis and in immuno-oncology.

Efficacy in NASH-Related Cirrhosis

The largest body of recent data stems from Phase 2b/3 trials investigating Galtes (or its active component, Belapectin) for the prevention of esophageal varices in patients with NASH-related cirrhosis. Results from the Phase 2b portion demonstrated a statistically significant reduction in the development of new varices in a subgroup of patients with compensated cirrhosis who were not already taking beta-blockers. The ongoing, seamless Phase 3 trial continues to evaluate this primary endpoint—prevention of esophageal varices—in a broader international patient population.

Study Phase Primary Focus Key Finding (Phase 2b)
Phase 2b/3 (Ongoing) Prevention of Esophageal Varices in NASH Cirrhosis Significant reduction in varices development in one subgroup

Role in Combination Cancer Therapy

In oncology, clinical studies have explored Galtes in combination with PD-1 checkpoint inhibitors (such as pembrolizumab). Preliminary Phase 1b data in subjects with advanced Head and Neck Squamous Cell Carcinoma (HNSCC) suggested that Galtes may enhance the clinical and immunological effects of the PD-1 inhibitor. Specifically, a subset of patients in this trial demonstrated an encouraging objective response rate. Further development in this area, including a company-sponsored Phase 2 program, is being actively pursued to confirm these initial findings in a larger cohort and to evaluate the safety profile in the context of combined immunotherapy.

Safety and Tolerability

Across multiple clinical trials, Galtes has generally been well-tolerated. The most common adverse events reported are typically mild to moderate in severity. The safety profile is continuously monitored in the ongoing large-scale trials, including the Phase 3 study for NASH-related cirrhosis and the trials in combination with other anti-cancer agents.

Key Studies & References The effects of transcutaneous electrical nerve stimulation during the first stage of labor: a randomized controlled trial (RCT)

Frequently Asked Questions (FAQ)

Common questions about Galtes (FAQ)


Q: Why do some people say Galtes made them feel a little sleepy?

A: Official product information suggests that sleepiness or confusion can be a symptom of hypoglycaemia (low blood sugar), which is a common adverse reaction to Galtes. If unexpected sleepiness or drowsiness occurs while taking this medication, it may be a sign that blood sugar levels are too low and may require intervention based on official guidance.

Q: Can Galtes be taken with common pain relievers like ibuprofen?

A: Regulatory documents indicate that taking Galtes with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can potentiate (increase) Galtes' blood-sugar-lowering effect. This interaction may raise the risk of hypoglycaemia. When these medications are used together, the combination may necessitate careful clinical monitoring of blood glucose levels, according to regulatory warnings.

Q: How long does Galtes stay in your system after you stop taking it?

A: The mean elimination half-life of Galtes (Gliclazide) is officially reported as approximately 10 to 13.5 hours. This pharmacokinetic data indicates that the majority of the substance is expected to be eliminated from the body within several days following the cessation of treatment.

Q: Is there any public research about how Galtes affects pregnant women?

A: Official guidance stipulates that Galtes is strictly contraindicated (prohibited) during pregnancy and lactation. During pregnancy, insulin is typically substituted to manage blood sugar, as the use of sulfonylureas is generally considered potentially harmful.

Q: Does Galtes cause weight gain or weight loss?

A: Official product information indicates that Galtes, which is a sulfonylurea, may encourage weight gain. Weight gain is a documented risk associated with this class of drugs, which work to improve blood sugar control in the body.

Q: Does Galtes affect blood sugar levels?

A: The primary function of Galtes is to actively lower elevated blood glucose levels. However, the official warnings highlight that it can cause low blood sugar (hypoglycaemia), which is classified as a common adverse reaction, especially when treatment begins or when the dose is adjusted.

Q: Is Galtes a new drug, or has it been around for a while?

A: Galtes (Gliclazide) is recognized as a second-generation sulfonylurea. The active substance is included on the WHO Model List of Essential Medicines, confirming that Gliclazide has a long-standing history of clinical use and is considered an important and established part of diabetes therapy worldwide.

Q: What are the contraindications for taking Galtes?

A: Official regulatory documents list several absolute reasons, or contraindications, that prohibit the use of Galtes. These include conditions such as Type 1 Diabetes, severe liver or kidney failure, diabetic ketoacidosis, being pregnant or breastfeeding, or concurrent use with the antifungal medicine miconazole.

Q: Do people develop a tolerance to Galtes over time?

A: Regulatory information notes that the effectiveness of any oral antidiabetic agent, including Galtes, can lessen over time. This condition is sometimes referred to as secondary failure and is typically due to the natural progression of the underlying diabetes condition, which may necessitate changes in the treatment plan.

Q: Is it common for Galtes to cause vivid dreams?

A: Vivid dreams are not listed as a specific common side effect in official reports. However, sleep disturbances or unusual dreams are sometimes reported as possible symptoms of a hypoglycaemic episode (low blood sugar), which is a common adverse effect of this medication.

Q: Can Galtes affect mood or cause anxiety?

A: Mood and behavioral changes, such as anxiety, agitation, or aggression, are documented as potential symptoms of a hypoglycaemic episode (low blood sugar). If these changes occur, it may indicate a need to review blood sugar management.

Q: How does Galtes interact with over-the-counter cold and flu medicine?

A: Official information indicates that various ingredients found in cold and flu remedies can affect blood sugar. Specifically, some components like beta-2 agonists or certain decongestants can either raise or lower blood glucose levels, potentially interfering with how Galtes works. Because of these potential effects, it is necessary to be aware of the active ingredients in all over-the-counter medications used.

Q: Does Galtes work by blocking a specific enzyme or receptor?

A: Galtes is an insulin secretagogue that works by binding to the sulfonylurea receptor (SUR1) located on the insulin-producing cells of the pancreas. This binding action closes specific potassium channels and triggers the body to release stored insulin, which assists in lowering blood glucose.

Q: Are there different strengths of Galtes tablets available?

A: Yes, regulatory information confirms that Galtes (Gliclazide) is available in several strengths in both standard-release and modified-release (MR) formulations. Available strengths typically include the 30 mg MR, 40 mg, 60 mg MR, and 80 mg tablets.

Q: What is the function of the inactive ingredients in Galtes?

A: The inactive ingredients, known as excipients, are essential for the physical integrity and release of the tablet. They ensure the active medicine, Gliclazide, is released into the body at the correct rate, particularly in the modified-release formulations. Regulatory documents note these ingredients and provide warnings for specific components like lactose.

Q: What are the known drug-to-drug interactions with Galtes?

A: The product labeling specifies that Galtes interacts with numerous medicines. The drug miconazole is strictly prohibited. Other classes like Beta-blockers and certain NSAIDs may increase the risk of low blood sugar, while medicines such as Glucocorticoids may reduce Galtes' effectiveness.

Q: How to Store and Dispose of Galtes (Gliclazide)?

A: Official guidelines state that Galtes should be stored at room temperature, below 25 C (77 F), and must be protected from both moisture and light. For disposal, official guidance recommends that unused or expired tablets be returned to a pharmacy or designated collection site for proper disposal, rather than being discarded in household waste or wastewater.

Q: Can Galtes affect my ability to drive or operate machinery?

A: Official information indicates that Galtes can impair your ability to drive or operate machinery, primarily due to the risk of hypoglycaemia (low blood sugar). It is essential for patients to be knowledgeable about the signs of low blood sugar, as these symptoms can impact the ability to concentrate and react while driving or operating equipment.

Q: What kind of medical monitoring is needed while taking Galtes?

A: Regulatory documents recommend regular monitoring of key markers while on Galtes. This typically includes checking blood glucose levels and glycated hemoglobin (HbA1c). Monitoring of liver function may also be recommended in some cases, as rare but serious hepatic side effects have been reported in official warnings.

How should Galtes be stored and disposed of?

How to Store and Dispose of Galtes (Gliclazide)

The storage and disposal of Galtes (Gliclazide) tablets must adhere strictly to official regulatory guidelines to maintain product stability and ensure safety.


Required Storage Conditions

Condition Requirement
Temperature Store at room temperature, specifically below 25 C (77 F). Do not refrigerate or store above 30 C.
Protection Keep in the original container, tightly closed, and protect from light and moisture.
Child Safety Store the medicine out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Galtes must not be disposed of in household waste or wastewater. The product should be returned to a pharmacy or designated collection site for proper disposal in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Galtes found in:

A-Z Index: